InterMune (ITMN) Higher Following INFORM-1 Trial Data

November 3, 2009 11:53 AM EST

InterMune, Inc. (Nasdaq: ITMN) is 7% higher today after announcing, with Pharmasset, Inc. (Nasdaq: VRUS) and partner Roche, results from all patient cohorts of the INFORM-1 trial in hepatitis C.

The company said, "The full dose combination of RG7128 1000mg and RG7227 900mg administered twice-daily without pegylated interferon or ribavirin, the current standard of care for HCV, for 13 days resulted in 88% of HCV-positive treatment-naive patients achieving HCV RNA below the lower limit of quantification (LLOQ; <43 IU/mL), and 63% of patients having HCV RNA below the lower limit of detection (LLOD; <15 IU/mL). The same regimen in "null responders" resulted in 50% of patients with HCV RNA below LLOQ and 25% of patients with HCV RNA below LLOD. Null responders were defined as patients with an HCV RNA reduction of <1 log10 IU/mL in 4 weeks or <2 log10 IU/mL in 12 weeks of prior treatment with pegylated interferon and ribavirin. At the twice-daily dose of 600mg of RG7227 in combination with 1000mg of RG7128 twice-daily for 13 days in treatment-experienced patients, somewhat lower viral load reduction and categorical responses were observed, an observation that will guide dosing in future studies in these patients."

Analysts at Merriman Curhan Ford said the "data presented were robust given the nature of the trial design."

Related Categories

FDA

Stocks Mentioned

Related Entities

• Merriman Curhan Ford

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?